All Stories

  1. Rapid eye movement sleep: Who needs it? Creativity mechanisms and psychiatric applications of REM sleep enhancement
  2. The WiserAD Trial: Protocol for the Pragmatic, Randomised Controlled Trial of a Structured Online Support Intervention to Inform and Assist Antidepressant Deprescribing in Primary Care. (Preprint)
  3. Structured Online Support to Inform and Assist Antidepressant Deprescribing in Primary Care: Protocol for a Pragmatic, Randomized Controlled Trial (The WiserAD Trial) (Preprint)
  4. Psychedelics, entactogens and psychoplastogens for depression and related disorders
  5. International Union of Basic and Clinical Pharmacology CXIV: Orexin Receptor Function, Nomenclature and Pharmacology
  6. On the kinetic features of orexin receptor antagonists at orexin receptors, transduction systems and receptor binding
  7. On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.
  8. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
  9. Orexin 2 receptor antagonism sex‐dependently improves sleep/wakefulness and cognitive performance in tau transgenic mice
  10. Orexin receptors in GtoPdb v.2023.1
  11. Altered EEG power spectrum, but not sleep-wake architecture, in HCN1 knockout mice
  12. Orexin Signaling: A Complex, Multifaceted Process
  13. Losing sleep with age
  14. Differential sleep/wake response and sex differences following acute suvorexant, MK‐1064 and zolpidem administration in the rTg4510 mouse model of tauopathy
  15. Hypocretins (orexins): The ultimate translational neuropeptides
  16. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
  17. Orexin receptors in GtoPdb v.2021.3
  18. Development of a LC-ESI-MRM method for the absolute quantification of orexin A in the CSF of individual mice
  19. Reward motivation and cognitive flexibility in tau null-mutation mice
  20. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm
  21. Manipulation of rapid eye movement sleep via orexin and GABAA receptor modulators differentially affects fear extinction in mice: effect of stable versus disrupted circadian rhythm
  22. Decreased Orexin Receptor 1 mRNA Expression in the Locus Coeruleus in Both Tau Transgenic rTg4510 and Tau Knockout Mice and Accompanying Ascending Arousal System Tau Invasion in rTg4510
  23. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function
  24. Serotoninergic System
  25. Targeting the 5-HT system: Potential side effects
  26. Effects of orexin receptor antagonism on human sleep architecture: A systematic review
  27. Circadian disruption impairs fear extinction and memory of conditioned safety in mice
  28. The Killing Mechanism of Teixobactin against Methicillin-Resistant Staphylococcus aureus: an Untargeted Metabolomics Study
  29. Long-term Outcomes After Controlled Oxygenated Rewarming of Human Livers Before Transplantation
  30. SMAD4 protein is decreased in the dorsolateral prefrontal and anterior cingulate cortices in schizophrenia
  31. Curcumin Attenuates Colistin-Induced Peripheral Neurotoxicity in Mice
  32. Hypnotics with novel modes of action
  33. Separating Probability and Reversal Learning in a Novel Probabilistic Reversal Learning Task for Mice
  34. Distribution of 5-HT receptors in the central nervous system: an update
  35. Synthesis and structure−activity relationships of teixobactin
  36. The BJP expects authors to share data
  37. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors
  38. Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa
  39. Delineating the influence of orexin 1 and 2 receptors on sleep architecture and aversive memory
  40. T-2 toxin neurotoxicity: role of oxidative stress and mitochondrial dysfunction
  41. Sex: A change in our guidelines to authors to ensure that this is no longer an ignored experimental variable
  42. The impact of backbone N ‐methylation on the structure‐activity relationship of Leu 10 ‐teixobactin
  43. Sex differences in mouse models of fear inhibition: Fear extinction, safety learning, and fear–safety discrimination
  44. Serotonin receptors nomenclature
  45. Contemporary Anti-Ebola Drug Discovery Approaches and Platforms
  46. Molecular Mechanisms of Neurotoxicity Induced by Polymyxins and Chemoprevention
  47. “The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites” Elena K. Schneider, Rachel M. McQuade, Vincenzo C. Carbone, Felisa Reyes-Ortega, John W. Wilson, Brenda Button, Ayame Saito, Daniel P. Poole, Daniel H...
  48. A Comparative Study of Outer Membrane Proteome between Paired Colistin-Susceptible and Extremely Colistin-Resistant Klebsiella pneumoniae Strains
  49. Reply to Tosh et al.: Quantitative analyses of cultural evolution require engagement with historical and archaeological research
  50. Animal Models of Addiction and Neuropsychiatric Disorders and Their Role in Drug Discovery: Honoring the Legacy of Athina Markou
  51. Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules
  52. Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
  53. Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology
  54. The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites
  55. Lemborexant. Dual orexin receptor antagonist, Treatment of insomnia
  56. Mechanistic Insights From Global Metabolomics Studies into Synergistic Bactericidal Effect of a Polymyxin B Combination With Tamoxifen Against Cystic Fibrosis MDR Pseudomonas aeruginosa
  57. Polymyxins for CNS infections: Pharmacology and neurotoxicity
  58. Quantitative historical analysis uncovers a single dimension of complexity that structures global variation in human social organization
  59. Rapamycin Confers Neuroprotection against Colistin-Induced Oxidative Stress, Mitochondria Dysfunction, and Apoptosis through the Activation of Autophagy and mTOR/Akt/CREB Signaling Pathways
  60. Orexin Receptor Antagonists
  61. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview
  62. Updating the guidelines for data transparency in the British Journal of Pharmacology - data sharing and the use of scatter plots instead of bar charts
  63. 5-HT Receptor Nomenclature: Naming Names, Does It Matter? A Tribute to Maurice Rapport
  64. A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment
  65. Saving, changing and repairing lives
  66. Blunted 5-HT1A receptor-mediated responses and antidepressant-like behavior in mice lacking the GABAB1a but not GABAB1b subunit isoforms
  67. Astrocytes: Adhesion Molecules and Immunomodulation
  68. Hippocampal 5-HT7receptors signal phosphorylation of the GluA1 subunit to facilitate AMPA receptor mediated-neurotransmissionin vitroandin vivo
  69. Editorial: Reporting guidelines for psychopharmacology
  70. Orexin OX2 Receptor Antagonists as Sleep Aids
  71. The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors
  72. A focus on the enzymes for which there is pharmacological or therapeutic interest
  73. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors
  74. The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels
  75. The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors
  76. The Concise Guide to PHARMACOLOGY 2015/16: Other ion channels
  77. The Concise Guide to PHARMACOLOGY 2015/16: Transporters
  78. The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels
  79. The Concise Guide to PHARMACOLOGY 2015/16: Overview
  80. Discovery of 1 H -pyrazolo[3,4- b ]pyridines as potent dual orexin receptor antagonists (DORAs)
  81. Experimental design and analysis and their reporting: new guidance for publication in BJP
  82. Pathological Conditions Associated with the Disturbance of the 5-HT System
  83. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation
  84. Somatostatin
  85. Suvorexant for the treatment of insomnia
  86. SOM230: A New Therapeutic Modality for Cushing's Disease
  87. Molecular Basis of Purinergic Signal Metabolism by Ectonucleotide Pyrophosphatase/Phosphodiesterases 4 and 1 and Implications in Stroke*
  88. Somatostatin
  89. The Concise Guide to PHARMACOLOGY 2013/14: Overview
  90. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?
  91. An invitation for comprehensive single-compound reviews on the pharmacological properties of newly launched drugs
  92. Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia
  93. Adult siRNA-induced knockdown of mGlu7 receptors reduces anxiety in the mouse
  94. Distinct effects of IPSU and suvorexant on mouse sleep architecture
  95. Kinetic properties of “dual” orexin receptor antagonists at OX1R and OX2R orexin receptors
  96. The Dual Orexin Receptor Antagonist Almorexant Induces Sleep and Decreases Orexin-Induced Locomotion by Blocking Orexin 2 Receptors
  97. Neuropeptides and Neuropeptide Receptors: Drug Targets, and Peptide and Non-Peptide Ligands: a Tribute to Prof.Dieter Seebach
  98. Neuropeptidomics of mouse hypothalamus after imipramine treatment reveal somatostatin as a potential mediator of antidepressant effects
  99. The Making of the 5-HT2C Receptor
  100. Reviewer comments on Reflections on drug research by Sir James Black
  101. Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats
  102. Neuropeptide receptor positive allosteric modulation in epilepsy: Galanin modulation revealed
  103. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias
  104. Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst3 receptor antagonists
  105. Hippocampal sst1 receptors are autoreceptors and do not affect seizures in rats
  106. Reaction of Fe3(CO)12 with octreotide—chemical, electrochemical and biological investigations
  107. Distribution of 5-HT Receptors in the Central Nervous System
  108. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease
  109. NMR-Solution Structures and Affinities for the Human Somatostatin G-Protein-Coupled Receptors hsst1–5 of CF3 Derivatives of Sandostatin® (Octreotide)
  110. Somatostatin, Alzheimer's disease and cognition: An old story coming of age?
  111. Selective effects of benzodiazepines on the acquisition of conditioned taste aversion compared to attenuation of neophobia in C57BL/6 mice
  112. Novel, Potent, and Radio-Iodinatable Somatostatin Receptor 1 (sst1) Selective Analogues
  113. Discovery of novel non-peptidic β-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists
  114. New Perspective in Peptide Chemistry by N-Alkylation
  115. The selective nicotinic acetylcholine receptor α7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain
  116. Increased exploratory activity of APP23 mice in a novel environment is reversed by siRNA
  117. Molecular biology of 5-HT receptors
  118. Antidepressants Influence Somatostatin Levels and Receptor Pharmacology in Brain
  119. New Open-Chain and Cyclic Tetrapeptides, Consisting ofα-,β2-, andβ3-Amino-Acid Residues, as Somatostatin Mimics - A Survey
  120. The Enantiomer of Octreotate Binds to All Five Somatostatin Receptors with Almost Equal Micromolar Affinity - A Comparison withSANDOSTATIN®
  121. Pharmacological profile of somatostatin and cortistatin receptors
  122. The Rostral Anterior Cingulate Cortex Modulates the Efficiency of Amygdala-Dependent Fear Learning
  123. Improving Oral Bioavailability of Peptides by Multiple N-Methylation: Somatostatin Analogues
  124. Ergoline derivatives as highly potent and selective antagonists at the somatostatin sst1 receptor
  125. Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis
  126. mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity
  127. Identification and SAR of potent and selective non-peptide obeline somatostatin sst1 receptor antagonists
  128. SAR of the arylpiperazine moiety of obeline somatostatin sst1 receptor antagonists
  129. JN403, in vitro characterization of a novel nicotinic acetylcholine receptor α7 selective agonist
  130. Emerging use of non-viral RNA interference in the brain
  131. 5-HT-5 Receptors
  132. 5-HT-6 Receptor
  133. 5-HT-7 Receptor
  134. 5-HT-1F Receptor
  135. 5-HT-3 Receptor
  136. 5-Hydroxytryptamine Receptors
  137. ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: Identification, in vitro pharmacology, pharmacokinetic and biodistribution studies
  138. RNA interference as a therapeutic strategy for treating CNS disorders
  139. Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine
  140. Somatostatin receptors in wildtype and somatostatin deficient mice and their involvement in nitric oxide physiology in the retina
  141. The somatostatin sst1 receptor: an autoreceptor for somatostatin in brain and retina?
  142. Compensatory changes in the hippocampus of somatostatin knockout mice: upregulation of somatostatin receptor 2 and its function in the control of bursting activity and synaptic transmission
  143. Hyperdopaminergia and altered locomotor activity in GABAB1-deficient mice
  144. Interfering with the brain: Use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders
  145. Global Down-Regulation of Gene Expression in the Brain Using RNA Interference, with Emphasis on Monoamine Transporters and GPCRs: Implications for Target Characterization in Psychiatric and Neurological Disorders
  146. Correction: Opportunities in somatostatin research: biological, chemical and therapeutic aspects
  147. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells
  148. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain
  149. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain
  150. Binding and functional properties of the novel somatostatin analogue KE 108 at native mouse somatostatin receptors
  151. Coupling of human nicotinic acetylcholine receptors α7 to calcium channels in GH3 cells
  152. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures
  153. Somatostatin Receptor 1 Selective Analogues:  2. Nα-Methylated Scan†
  154. P.4.09 Behavioural and neurochemical consequencesof sIRNA-induced knockdown of serotonin and dopamine transporters in the adult mouse brain: Implications for validation of novel antidepressant targets
  155. Proceedings of Neuropeptides 2004, the XIV European Neuropeptides Club meeting
  156. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference
  157. Somatostatin receptors differentially affect spontaneous epileptiform activity in mouse hippocampal slices
  158. Paroxetine combined with a 5-HT1A receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats
  159. The NK1 receptor antagonist NKP608 lacks anxiolytic-like activity in Swiss-Webster mice exposed to the elevated plus-maze
  160. The somatostatin receptor (sst1) modulates the release of somatostatin in the nucleus accumbens of the rat
  161. Effect of Somatostatin on Nitric Oxide Production in Human Retinal Pigment Epithelium Cell Cultures
  162. Comparison of functional profiles at human recombinant somatostatin sst2receptor: simultaneous determination of intracellular Ca2+and luciferase expression in CHO-K1 cells
  163. SRA880, in vitro characterization of the first non-peptide somatostatin sst1 receptor antagonist
  164. Applications of a Rat Multiple Tissue Gene Expression Data Set
  165. Genetic deletion of somatostatin receptor 1 alters somatostatinergic transmission in the mouse retina
  166. Opportunities in somatostatin research: biological, chemical and therapeutic aspects
  167. S.24.05 Agonist-antagonist binding: Relevance for therapeutic action
  168. Withdrawal from chronic amphetamine induces Depressive-Like behavioral effects in rodents
  169. Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs
  170. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs
  171. Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists
  172. Biological activity of somatostatin receptors in GC rat tumour somatotrophs: evidence with sst1–sst5 receptor-selective nonpeptidyl agonists
  173. Design and Synthesis of γ-Dipeptide Derivatives with Submicromolar Affinities for Human Somatostatin Receptors
  174. β2/β3-di- and α/β3-tetrapeptide derivatives as potent agonists at somatostatin sst4 receptors
  175. Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806
  176. Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice
  177. Study of the calcium dynamics of the human α4β2, α3β4 and α1β1γδ nicotinic acetylcholine receptors
  178. Molecular, pharmacological and functional diversity of 5-HT receptors
  179. Identification and characterization of a type five-like somatostatin receptor in goldfish pituitary
  180. Somatostatin sst2 receptor knock-out mice: localisation of sst1–5 receptor mRNA and binding in mouse brain by semi-quantitative RT–PCR, in situ hybridisation histochemistry and receptor autoradiography
  181. Emerging discoveries in neuroscience: molecular bridges to the brain
  182. Pharmacological characterisation of the goldfish somatostatin sst5 receptor
  183. Drug Design at Peptide Receptors
  184. Extended Radioligand Binding Profile of Iloperidone A Broad Spectrum Dopamine/Serotonin/Norepinephrine Receptor Antagonist for the Management of Psychotic Disorders
  185. Linear, Peptidase-Resistantβ2/β3-Di- andα/β3-Tetrapeptide Derivatives with Nanomolar Affinities to a Human Somatostatin Receptor, Preliminary Communication
  186. Lack of evidence for cross-competition between vasoactive intestinal peptide and somatostatin at their respective receptors
  187. Peptide Folding Induces High and Selective Affinity of a Linear and Small β-Peptide to the Human Somatostatin Receptor 4
  188. Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery
  189. Somatostatin receptors and the potential use of Sandostatin to interfere with vascular remodelling
  190. Recovery of emotional behaviour in neural cell adhesion molecule (NCAM) null mutant mice through transgenic expression of NCAM180
  191. Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1
  192. Cloning, expression and pharmacological characterisation of the mouse somatostatin sst5 receptor
  193. Syntheses and biological activities of sandostatin analogs containing stereochemical changes in positions 6 or 8
  194. Cloning, expression, functional coupling and pharmacological characterization of the rat dopamine D 4 receptor
  195. Involvement of the Sst1 Somatostatin Receptor Subtype in the Intrahypothalamic Neuronal Network Regulating Growth Hormone Secretion: An in Vitro and in Vivo Antisense Study
  196. Potent and Selective Non-Peptidic Inhibitors of Endothelin-Converting Enzyme-1 with Sustained Duration of Action
  197. The Cyclo-β-Tetrapeptide (β-HPhe-β-HThr-β-HLys-β-HTrp): Synthesis, NMR Structure in Methanol Solution, and Affinity for Human Somatostatin Receptors
  198. Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies
  199. Characterisation of human recombinant somatostatin receptors. 2. Modulation of GTPγS binding
  200. Characterisation of human recombinant somatostatin receptors. 3. Modulation of adenylate cyclase activity
  201. Characterisation of human recombinant somatostatin receptors. 4. Modulation of phospholipase C activity
  202. Brain somatostatin: a candidate inhibitory role in seizures and epileptogenesis
  203. Receptor density as a factor governing the efficacy of the dopamine D4receptor ligands, L-745,870 and U-101958 at human recombinant D4.4receptors expressed in CHO cells
  204. Anxiety and increased 5-HT1A receptor response in NCAM null mutant mice
  205. Molecular Cloning and Pharmacological Characterization of a Somatostatin Receptor Subtype in the Gymnotiform Fish Apteronotus albifrons
  206. Pharmacological characterisation of 5-HT receptors positively coupled to adenylyl cyclase in the rat hippocampus
  207. Structural and compositional determinants of cortistatin activity
  208. Synthesis and Biological Evaluation of a Cyclo--tetrapeptide as a Somatostatin Analogue
  209. Characterisation of the fish sst3 receptor, a member of the SRIF1 receptor family: atypical pharmacological features
  210. Preface
  211. High Affinity of SDZ HTF-919 and Related Molecules for Calf and Human Caudate 5-HT4 Receptors
  212. Impact of the Human Genome Project on the Principles for Classification and Nomenclature of 5-HT Receptors
  213. The role ofα2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat
  214. Design, Synthesis, and Biological Activities of Potent and Selective Somatostatin Analogues Incorporating Novel Peptoid Residues
  215. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4receptor
  216. [125I]Tyr10-cortistatin14 labels all five somatostatin receptors
  217. [][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors
  218. The structure and signalling properties of 5-HT receptors: an endless diversity?
  219. Identification and pharmacological characterization of somatostatin receptors in rat lung
  220. 5-HT Receptor Classification and Nomenclature: Towards a Harmonization with the Human Genome
  221. Editorial
  222. Inhibition of cAMP Accumulation Via Recombinant Human Serotonin 5-HT 1A Receptors: Considerations on Receptor Effector Coupling across Systems
  223. Autoradiographic analysis of somatostatin SRIF1 and SRIF2 receptors in the human brain and pituitary
  224. Pharmacological characterisation of human cerebral cortex somatostatin SRIF1 and SRIF2 receptors
  225. Minireview: Nomenclature and Classification of Transmitter Receptors: an Integrated Approach
  226. Presence of somatostatin sst2 receptors in the developing rat auditory system
  227. Status of somatostatin receptor messenger RNAs and binding sites in rat brain during kindling epileptogenesis
  228. Expression of five somatostatin receptor mRNAs in the human brain and pituitary
  229. Binding properties of somatostatin receptor subtypes
  230. Localization and pharmacological characterization of somatostatin recognition sites in the human cerebellum
  231. Somatostatin receptors in the Rhesus monkey brain: localization and pharmacological characterization
  232. Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes
  233. SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity
  234. Somatostatin receptors in the developing rat brain
  235. SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors
  236. Classification and nomenclature of 5-HT receptors: a comment on current issues
  237. Embryonic and postnatal mRNA distribution of five somatostatin receptor subtypes in the rat brain
  238. Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera
  239. Localization and pharmacological characterization of somatostatin sst2 sites in the rat cerebellum
  240. The Serotonin 5-HT4 Receptor. 1. Design of a New Class of Agonists and Receptor Map of the Agonist Recognition Site
  241. The Serotonin 5-HT4 Receptor. 2. Structure-Activity Studies of the Indole Carbazimidamide Class of Agonists
  242. Functional effects of d-Phe-c[Cys-Tyr-d-Trp-Lys-Val-Cys]-Trp-NH2 and differential changes in somatostatin receptor messenger RNAs, binding sites and somatostatin release in kainic acid-treated rats
  243. Characterization and distribution of somatostatin SS-1 and SRIF-1 binding sites in rat brain: identitity with SSTR-2 receptors
  244. Classification and nomenclature of somatostatin receptors
  245. Pharmacological identity between somatostatin SS-2 binding sites and SSTR-1 receptors
  246. Co-expression of somatostatin SSTR-3 and SSTR-4 receptor messenger RNAs in the rat brain
  247. (+)-cis-4,5,7a,8,9,10,11,11a-Octahydro-7H-10-methylindolo[1,7-bc][2,6]- naphthyridine: A 5-HT2C/2B Receptor Antagonist with Low 5-HT2A Receptor Affinity
  248. Therapeutic Possibilities with Serotonergic Drugs
  249. Molecular pharmacology of somatostatin receptors
  250. Aspartyl .alpha.-((1-Phenyl-3-(trifluoromethyl)- pyrazol-5-yl)oxy)methyl Ketones as Interleukin-1.beta. Converting Enzyme Inhibitors. Significance of the P1 and P3 Amido Nitrogens for Enzyme-Peptide Inhibitor Binding
  251. Chromic mianserin or eltoprazine treatment in rats: effects on the elevated plus-maze test and on limbic 5-HT2C receptor levels
  252. Molecular Pharmacology of Somatostatin-receptor Subtypes
  253. Localization of 5-HT1B, 5-HT1Dα, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain
  254. Localization of somatostatin (SRIF) SSTR-1, SSTR-2 and SSTR-3 receptor mRNA in rat brain by in situ hybridization
  255. A comparative autoradiographic study of 5-HT1D binding sites in human and guinea-pig brain using different radioligands
  256. Differential Expression of Five Somatostatin Receptor Subtypes, SSTR1-5, in the CNS and Peripheral Tissue
  257. Effect of 5,7-dihydroxytryptamine lesion on mianserin-induced conditioned place aversion and on 5-hydroxytryptamine1C receptors in the rat brain
  258. Endothelin receptors in the human coronary artery, ventricle and atrium
  259. Distribution and second messenger coupling of four somatostatin receptor subtypes expressed in brain
  260. Calcineurin inhibits desensitization of cloned rat 5-HT1C receptors
  261. Partial agonists, full agonists, antagonists: dilemmas of definition
  262. The novel 5-HT1A receptor antagonist, SDZ 216-525, decreases 5-HT release in rat hippocampus in vivo
  263. A proposed new nomenclature for 5-HT receptors
  264. Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain
  265. 5-Hydroxytryptamine1 recognition sites in rat brain: Heterogeneity of non-5-hydroxytryptamine1a/1c binding sites revealed by quantitative receptor autoradiography
  266. SDZ 216–525, a selective and potent 5-HT1A receptor antagonist
  267. Characterization of functional responses in A9 cells transfected with cloned rat 5-HT1C receptors
  268. A Reappraisal of 5-HT Receptor Classification
  269. Evidence for the presence of 5-HT1B receptor messenger RNA in neurons of the rat trigeminal ganglia
  270. 5-HT1D binding sites in various species: similar pharmacological profile in dog, monkey, calf, guinea-pig and human brain membranes
  271. ?5-HT1R? or 5-HT1D sites? Evidence for 5-HT 1D binding sites in rabbit brain
  272. Agonist/antagonist interactions with cloned human 5-HT1A receptors: variations in intrinsic activity studied in transfected HeLa cells
  273. Direct visualization of serotonin1D receptors in the human brain using a new iodinated radioligand
  274. 5-Hydroxytryptamine (5-HT) receptor superfamilies
  275. Homogeneous 5-HT1D recognition sites in the human substantia nigra identified with a new iodinated radioligand
  276. Competitive antagonism by recognised 5-HT2 receptor antagonists at 5-HT1C receptors in pig choroid plexus
  277. Interaction of the α-adrenoceptor agonist oxymetazoline with serotonin 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors
  278. 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of guinea-pig isolated iliac artery
  279. Receptor biochemistry and methodology volume 15: Serotonin receptor subtypes
  280. 5-HT Receptors: Subtypes and Second Messengers
  281. Autoradiography of 5-HT receptors: A critical appraisal
  282. Interaction between systemic circulation and brain injuries in newborns
  283. Investigations of cerebral glucose utilization into the newborn brain: A [18F]-FDG positron emission tomography study using a high resolution multiwire proportional chamber detector device
  284. Distribution of Serotonin Receptors
  285. Serotonin 5‐HT1D Receptors
  286. The serotonin 5-HT1D receptor: A progress review
  287. Receptor modification in the brains of spontaneously hypertensive and Wistar-Kyoto rats: regionally specific and selective increase in cerebellar beta 2-adrenoceptors.
  288. Similar distribution of [125I]sarafotoxin-6b and [125I]endothelin-1, -2, -3 binding sites in the human kidney
  289. Selective Agonists and Antagonists at 5-Hydroxytryptamine Receptor Subtypes
  290. Subtypes of α1-adrenoceptors in hippocampus of pigs, guinea-pigs, calves and humans: regional differences
  291. Interaction of psychotropic drugs with central 5-HT3 recognition sites: fact or artifact?
  292. 5-HT1D receptors in guinea-pig and pigeon brain
  293. 5.HT1 receptors in the vertebrate brain
  294. A Comparison of the Interactions of Dihydroergotamine, Ergotamine and GR 43175 with 5-HT1 Receptor Subtypes
  295. [3H]ICS 205-930 labels 5-HT3 recognition sites in membranes of cat and rabbit vagus nerve and superior cervical ganglion
  296. 5-Hydroxytryptamine 5-HT1B and 5-HT1D receptors mediating inhibition of adenylate cyclase activity
  297. Is the sumatripan (GR 43175)-induced endothelium-dependent relaxation of pig coronary arteries mediated by 5-HT1D receptors?
  298. The pharmacological properties of the presynaptic serotonin autoreceptor in the pig brain cortex conform to the 5-HT1D receptor subtype
  299. How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors
  300. Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?
  301. Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain
  302. 5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus
  303. 5-Hydroxytryptamine3 receptors in the human brain: Autoradiographic visualization using [3H]ICS 205-930
  304. Competitive Interaction of Agonists and Antagonists with 5-HT3-Recognition Sites in Membranes of Neuroblastoma Cells Labelled with [3H] ICS 205–930
  305. GR 43175: A preferential 5‐HT1D agent in monkey and human brains as shown by autoradiography
  306. [125I]Endothelin-l Binding Sites
  307. Centrally acting hypotensive agents with affinity for 5‐HT1A binding sites inhibit forskolin‐stimulated adenylate cyclase activity in calf hippocampus
  308. Localisation by autoradiography of neuronal 5-HT3 receptors in the mouse CNS
  309. Molecular pharmacology of 5-HT1D recognition sites: Radioligand binding studies in human, pig and calf brain membranes
  310. The 5-hydroxytryptamine 5-HT1D receptor subtype is negatively coupled to adenylate cyclase in calf substantia nigra
  311. Characterisation of 5-HT3 recognition sites in membranes of NG 108-15 neuroblastoma-glioma cells with [3H]ICS 205-930
  312. Visualization of a novel serotonin recognition site (5-HT1D) in the human brain by autoradiography
  313. [125I]SCH 23982, a ‘selective’ D-1 receptor antagonist, labels with high affinity 5-HT1C sites in pig choroid plexus
  314. Central 5-HT1A Receptors and the Mechanism of the Central Hypotensive Effect of (+)8-OH-DPAT, DP-5-CT, R28935, and Urapidil
  315. Identification of a 5-HT1 recognition site in human brain membranes different from 5-HT1A, 5-HT1B and 5-HT1C sites
  316. Molecular pharmacology and biology of 5-HT1C receptors
  317. 5-HT1D receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in calf substantia nigra
  318. Functional Correlates of Serotonin 5-HT1Recognition Sites
  319. Identification of serotonin 5-HT3 recognition sites by radioligand binding in NG108-15 neuroblastoma-glioma cells
  320. α1-adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates
  321. [3H]Ketanserin labels 5-HT2 receptors and ?1-adrenoceptors in human and pig brain membranes
  322. [3H]Ketanserin Labels Serotonin 5-HT2 and α1-Adrenergic Receptors in Human Brain Cortex
  323. Inhibition of 5-carboxamidotryptamine-induced relaxation of guinea-pig ileum correlates with [125I]LSD binding
  324. [125I]LSD labels 5-HT1C recognition sites in pig choroid plexus membranes. Comparison with [3H]mesulergine and [3H]5-HT binding
  325. 5-HT1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus
  326. Serotonin increases the production of inositol phosphates and mobilises calcium via the 5-HT2 receptor in A7r5 smooth muscle cells
  327. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites
  328. Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites
  329. Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites
  330. Implications of stereoselectivity in radioligand binding studies
  331. Characterization of the 5-HTIB recognition site in rat brain: Binding studies with (−)[125I]Iodocyanopindolol
  332. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: Radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (−)[125I]iodocyanopindolol, [3H]mesulergine and [3H]Ketanserin
  333. Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine and human cortex: Evidence for species differences in brain serotonin-2 receptors
  334. The binding of serotonergic ligands to the porcine choroid plexus: Characterization of a new type of serotonin recognition site
  335. Characterization of IBE 2254 Binding to Alpha - Adrenergic Receptors on Intact DDT Smooth Muscle Cells: Comparison with Membrane1Binding and Correlation with Phosphoinositides Breakdown
  336. Identification of 5HT2-Receptors on Longitudinal Muscle of the Guinea Pig Ileum
  337. Binding of125I-Cyanopindolol to Beta-1-Adreno-Ceptors in a High and Low Affinity State
  338. Non-specific uptake of the radioligand 125I-IHYP by intact human lymphocytes: Reversal of the uptake process
  339. Binding characteristics of (+)-, (�)- and (-)-[125Iodo] cyanopindolol to guinea-pig left ventricle membranes
  340. [125Iodo]BE 2254, a New Radioligand for α1-Adrenoceptors
  341. (�)[125Iodo]cyanopindolol, a new ligand for ?-adrenoceptors: Identification and quantitation of subclasses of ?-adrenoceptors in guinea pig
  342. The β-adrenergic receptor in human lymphocytes: Subclassification by the use of a new radio-ligand, (±)−125iodocyanopindolol
  343. [125I]BE 2254, a new high affinity radioligand for α1-adrenoceptors
  344. Effects of some GABA-mimetic drugs on the antinociceptive activity of morphine and ?-endorphin in rats
  345. Assessing allosteric ligand-receptor interactions
  346. Molecular biology of 5-HT receptors
  347. Highly N-Methylated Somatostatin Analogs: Synthesis, Biological Activity and Structure-Activity Relationship Studies
  348. Serotoninergic System
  349. Somatostatin Receptor Gene Family - Subtype Selectivity for Ligand Binding